GlassScriptPhysician profile
James Andrew Burtka
NPI 1972593499
$7,007.85
in general payments reported to CMS, 2019-2025
29 companies · $784 in 2025
The $784 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $723 · 2020: $637 · 2021: $1,851 · 2022: $1,288 · 2023: $1,147 · 2024: $578 · 2025: $784.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,449 · Consulting Fee: $60.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,448.90 |
| Consulting Fee | $60.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,624.61 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,000.66 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $689.92 | 2019-2025 | |
| Amarin Pharma, INC. | $567.07 | 2019-2022 | |
| Amgen INC. | $515.70 | 2019-2025 | Repatha, Otezla, Repatha |
| Esperion Therapeutics, INC. | $513.22 | 2020-2025 | Nexletol |
| Glaxosmithkline, LLC. | $480.37 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $261.71 | 2020-2025 | Zepbound, Mounjaro |
| Janssen Pharmaceuticals, INC | $193.23 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.87 | 2020-2023 | Jardiance, Tradjenta, Synjardy |
| Idorsia Pharmaceuticals US INC | $121.39 | 2022-2023 | Quviviq |
| Exact Sciences Corporation | $120.21 | 2023-2025 | Cologuard Collection Kit |
| Vanda Pharmaceuticals INC. | $109.82 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $99.55 | 2021-2023 | |
| Currax Pharmaceuticals LLC | $80.15 | 2020-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $77.70 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $52.90 | 2019 | |
| Genentech USA, INC. | $49.91 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $48.66 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $41.59 | 2022 | |
| Horizon Therapeutics Plc | $39.23 | 2022-2023 | Krystexxa |
| Merck Sharp & Dohme LLC | $37.75 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $33.08 | 2021-2024 | Eliquis |
| Astellas Pharma US INC | $26.36 | 2019-2020 | |
| Abbvie INC. | $20.32 | 2021 | |
| Daiichi Sankyo INC. | $15.81 | 2022 | |
| Sanofi Pasteur INC. | $14.69 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $13.12 | 2022 | |
| Dexcom, INC. | $12.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Burtka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.